Compounds > nanterinone
Page last updated: 2024-12-06

nanterinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nanterinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71305
CHEMBL ID37971
SCHEMBL ID563806
MeSH IDM0170593

Synonyms (24)

Synonym
102791-47-9
uk-61260
uk-61260-27
nanterinone
CHEMBL37971
6-(2,4-dimethylimidazol-1-yl)-8-methyl-1h-quinolin-2-one
uk-61,260
nanterinone [inn:ban]
2(1h)-quinolinone, 6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methyl-
6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-quinolone
unii-1s169l7kav
1s169l7kav ,
nanterinone [inn]
nanterinone [mart.]
2(1h)-quinolinone,6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methyl-
SCHEMBL563806
8-methyl-6-(2,4-dimethylimidazol-1-yl)-2-(1h)-quinolone
8-methyl-6-(2,4-dimethylimidazol1-yl)-2-(1h)-quinolone
NMNXBEXPAHSXOK-UHFFFAOYSA-N
DTXSID70145513
6-(2,4-dimethyl-1h-imidazol-1-yl)8-meth-yl-2(1h)-quinolone
6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methylquinolin-2(1h)-one
Q27252817
AKOS040753210

Research Excerpts

Overview

Nanterinone (UK-61,260) is a novel positive inotropic and balanced-type vasodilating drug. Only partially based on phosphodiesterase III inhibition.

ExcerptReferenceRelevance
"Nanterinone (UK-61,260) is a novel positive inotropic and balanced-type vasodilating drug, only partially based on phosphodiesterase III inhibition. "( Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
Bartels, GL; Krauss, XH; Kruijssen, HA; Remme, WJ; Storm, CJ; van der Ent, M; van Hoogenhuyze, DC; van Schelven, D, 1996)		1.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID58757Relative inotropic potency compared with 4-[4-[2-(1,1-dioxo-2-isothiazolidinyl)ethyl]-1-piperidinyl]-6,7-dimethoxyquinazoline at 50 ug/kg after administration at 12.5 ug/kg intravenously to anesthetized dogs1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives.
AID25583Dissociation constant was determined1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
7-Heteroaryl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin -2(1H)-one derivatives with cardiac stimulant activity.
AID60036Compound was tested for cardiotonic activity after intravenous administration of 12.5 ug/Kg to anesthetized dogs1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives.
AID606590.25 mg/kg of compound was administered orally to conscious adult Beagle dogs and the effects on cardiac contractility was determined after 1 hr1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives.
AID60796Compound was examined for effects on cardiac contractility after oral administration of 0.25 mg/Kg to conscious dogs for 1 hr1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives.
AID60801Compound was examined for effects on cardiac contractility to decrease in QA interval after oral administration of 0.25 mg/Kg to conscious dogs for 3h1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives.
AID58749Inotropic potencies relative to 4-[4-[2-(1,1-dioxo-2-isothiazolidinyl)ethyl]-1-piperidinyl]-6,7-dimethoxyquinazoline (50 ug/kg) in anesthetized dog1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives.
AID607860.25 mg/kg of compound was administered orally to conscious adult Beagle dogs and the effects on cardiac contractility was determined after 3 hr1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives.
AID59896Positive inotropic activity after intravenous administration of 12.5 ug/kg (dose) to anesthetized dog1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (50.00)18.7374
1990's3 (37.50)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fenoldopam
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.		1.9810benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
milrinone
[no description available]		2.6630bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		4.4751monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
colforsin
Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.		1.9810acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		3.3711dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
quazinone
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Aneurysm, Ruptured
The tearing or bursting of the weakened wall of the aneurysmal sac, usually heralded by sudden worsening pain. The great danger of a ruptured aneurysm is the large amount of blood spilling into the surrounding tissues and cavities, causing HEMORRHAGIC SHOCK.		02.0510
Abdominal Aortic Aneurysm
[description not available]		02.0510
Aortic Aneurysm, Abdominal
An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.		02.0510
Bleeding
[description not available]		01.9810
Essential Polyarteritis
[description not available]		01.9810
Hemorrhage
Bleeding or escape of blood from a vessel.		01.9810
Left Ventricular Dysfunction
[description not available]		03.3711
Cardiac Failure
[description not available]		03.3711
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		08.3711
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		03.3711